Milestone Pharmaceuticals Inc. - 10-Q Filing
Milestone Pharmaceuticals Inc. filed its quarterly report for March 31, 2026, disclosing financial results including a net loss of $45.8 million compared to $39.7 million in the same period last year. The company reported research and development expenses of $32.4 million versus $27.9 million YoY and general administrative costs of $13.0 million vs. $10.6 million YoY.
Tickers: $MIST